Gevorg Tamamyan: Waiting to see promising bot/bal results from our lung cancer trial

Gevorg Tamamyan posted on LinkedIn:

“Just saw the presentation from ESMO GI Annual Congress and the outstanding results after neoadjuvant botensilimab and balstilimab in colorectal cancer. The images are from a 40-year-old female with Stage 3 MSS Colorectal Cancer (CRC), after 7 weeks with BOT/BAL therapy – complete response (100% tumor reduction)! Congratulations to all the great team of investigators – Pashtoon Kasi and colleagues and of course, wonderful Agenus team!

Waiting for similar results also from our lung cancer trial with BOT/BAL (NCT06322108), conducted by our Immune Oncology Research Institute.
We need to hurry up, because cancer and patients cannot wait!”

Source: Gevorg Tamamyan/LinkedIn

Gevorg Tamamyan is the Editor-in-chief of OncoDaily, Head of the Pediatric Cancer and Blood Disorders Center of Armenia, Chairman and Professor of the Department of Hematology and Pediatric Oncology at Yerevan State Medical University, CEO of the Immune Oncology Research Institute, President-Elect of the Pediatric Oncology East and Mediterranean (POEM) Group.

He is also the Adviser to the Rector of YSMU and to the Director of the Yeolyan Hematology and Oncology Center. He is a Co-Founder and Board Member of the Armenian Association of Hematology and Oncology, City of Smile Charitable Foundation, Co-Founder and Chairman of the Board of the Institute of Cancer and Crisis, the Former President of the Harvard Club of Armenia.

.